Home › Companies › IONS

Ionis Pharmaceuticals

Market cap $4.49B 166.5M shares (10-Q, Nov 3, 2026) × $26.96 close Nov 17, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Eplontersen ATTR-CM filing2026Eplontersen ATTR-CM filing, 2026, notable
  2. Pelacarsen filing2026Pelacarsen filing, 2026, notable
  3. Ionis corporate updateOct–Nov 2026Ionis corporate update, Oct–Nov 2026, material
  4. Obudanersen Ph3 topline2027Obudanersen Ph3 topline, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (29 active programs)

Technology platforms

MsPA backbone chemistry

Mesyl phosphoramidate backbone chemistry designed to improve therapeutic index and durability by increasing metabolic stability, improving potency and reducing non-specific protein interactions; multiple new programs in preclinical development

Bicycle technology · Bicycle Therapeutics

Bicyclic peptide technology licensing collaboration with Bicycle Therapeutics to expand LICA platform for delivery of oligonucleotides to skeletal and cardiac muscle and potentially across the blood-brain barrier via transferrin receptor 1 binding

Targets: transferrin receptor 1

Vect-Horus technology · Vect-Horus

Camelid-derived antibody platform licensed exclusively for systemic delivery of RNA-targeted therapeutics across the blood-brain barrier to CNS targets; first program advanced to preclinical development in 2025

Metagenomi gene editing · Metagenomi

Collaboration leveraging RNA-targeted therapeutics expertise combined with Metagenomi next-generation CRISPR-Cas gene editing systems to discover and develop drugs for validated and novel genetic targets; up to eight targets total

Vect-Horus · Vect-Horus

Systemic delivery platform for RNA-targeted therapeutics using camelid-derived single-domain antibodies to cross the blood-brain barrier and address CNS targets; focus area: central nervous system diseases

Discontinued (1)

Capital (as filed)

Cash
$296M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$1.59B Sep 30, 2026
Long-term investments
$561M Sep 30, 2026
Operating cash flow
−$179M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.88B cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Ionis Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Ionis Pharmaceuticals (IONS) — Scientific Deep Dive for Olezarsen, Zilganersen and the RNA-Targeted Pipeline Science is proven and balance sheet is funded, but the flagship TRYNGOLZA booked only $4.6M in Q2 against a >$3B peak-sales claim, making it prudent to wait for one clean print at the new price before committing.
  2. Watch UPDATE: Ionis Pharmaceuticals (IONS) - The Streak Breaks FUSION's Phase 3 win repairs scientific credibility but does not answer the commercial question; TRYNGOLZA's Q3 print remains the gating event.
  3. Watch UPDATE: Ionis Pharmaceuticals (IONS) - Two for Two, Minus the Number Sefaxersen's Phase 3 proteinuria win is a second positive readout in 48 hours but provides no number and does not address the TRYNGOLZA commercial question.
  4. Watch UPDATE: Ionis Pharmaceuticals (IONS) - Approved, With a Box on It Bepirovirsen approval retires regulatory risk on the best partnered asset but the boxed label, China carve-out, and capped royalty leave the TRYNGOLZA commercial question as the sole gating event.
  5. Watch UPDATE: Ionis Pharmaceuticals (IONS) - Here's the Number Sefaxersen's 43.1% proteinuria reduction is real and regulator-relevant but does not clearly beat iptacopan and does nothing for the TRYNGOLZA commercial question.
  6. Avoid UPDATE: Ionis Pharmaceuticals (IONS) - The $9 Million Answer TRYNGOLZA's $9.3M Q3 print decisively failed the pre-committed <$20M Pass trigger, with guidance cut in half and no sequential growth projected for Q4, making the >$3B peak-sales claim dependent on an untested 2027 payer cycle.
  7. Avoid UPDATE: Ionis Pharmaceuticals (IONS) - The Tau Gap Closes, Partly Diranersen's Week 96 functional signal and EU TRYNGOLZA approval are positive for the science but neither addresses the U.S. demand failure that triggered the downgrade.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (33)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)